AbbVie Inc (4AB) Fair Value & Analysis
Healthcare · DE · Market cap €381B
Fair value as of: Jul 12, 2026
From 24 valuation models · updated 2 days ago
Share price +9.7% over the past month.
Price vs Fair Value (12 months)
12‑month range €155.73 – €227.20 · fair‑value band €39.47 – €98.88 · the €213.59 price screens above the €67.72 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
AbbVie Inc (4AB) currently trades at €213.59, while our model-based Fair Value estimate is €67.72 — implying the stock looks roughly 68.3% overvalued today. We read business quality at 74/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, AbbVie Inc generated revenue of €62.8B at a net margin of 5.8%. Revenue grew 12.4% year over year. It earns a return on equity of 62.3%. Net debt stands at €63.8B. Fundamentals as of Jul 12, 2026
Our scenario range runs from €39.47 (bear case) to €98.88 (bull case); at €213.59, the current price sits above that range. The share trades near its 52-week high and 42% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside — at -68%, 4AB screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AbbVie Inc reported revenue of €61.2B in FY2025 versus €56.2B in FY2021, a compound +2.1%/yr. Reported net income was €4.2B in FY2025, compounding −22.2%/yr from FY2021.
Is 4AB fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | C$29.84 | C$23.01 | -23% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| AstraZeneca PLC ZEG | €160.70 | €109.08 | -32% |
| Novo Nordisk A/S NOV | €39.18 | €38.90 | -1% |
| Amgen Inc AMGN | $344.72 | $261.17 | -24% |
| Gilead Sciences, Inc GILD34 | R$314.88 | R$283.11 | -10% |
| Pfizer Inc PFE | $25.08 | $20.67 | -18% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AbbVie Inc (4AB) undervalued?
What is the fair value of 4AB?
What is the quality score of 4AB?
What is the revenue of AbbVie Inc (4AB)?
What is the net profit margin of 4AB?
Does AbbVie Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full AbbVie Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.